Journal
NEUROLOGY
Volume 90, Issue 6, Pages 257-259Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000004936
Keywords
-
Categories
Funding
- NINDS NIH HHS [U54 NS065712] Funding Source: Medline
Ask authors/readers for more resources
Sandelius et al.(1) identify neurofilament light (NfL) as a potential biomarker for different types of Charcot-Marie-Tooth disease (CMT) in the current issue of Neurology (R). NfL is increased in CSF and serum in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS).(1) The reader may question, therefore, what is so special about it being identified as a biomarker for yet another disorder. The answer is that clinical trials are emerging for several CMT forms and the lack of a nerve-specific biomarker has been a limiting factor in designing and performing these trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available